Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4095-4099

  Zheng, Lu ^a   Gong, Wei ^a   Liang, Ping ^a   Huang, XiaoBing ^a   You, Nan ^a   Han, Ke Qiang ^a   Li, Yu Ming ^a   Li, Jing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Fetoprotein; Hepatocellular carcinoma cells; Migration; PI3K Akt; Proliferation; Signaling pathway

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA FETOPROTEIN; ALPHA FETOPROTEIN MONOCLONAL ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HEPATITIS B; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STABLE EXPRESSION; VIRUS HEPATITIS; WESTERN BLOTTING; GENETICS; LIVER TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ALPHA-FETOPROTEINS; CELL PROLIFERATION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84902984014     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1535-z     Document Type: Article

References (19)

1. Zhao Y, Wang Q, Deng X, Shi P, Wang Z. Quantitative assessment of the association between GSTP1 gene Ile105Val polymorphism and susceptibility to hepatocellular carcinoma. Tumour Biol. 2013;34:2121-6.
2. Wu D, Jiang H, Gu Q, Zhang D, Li Z. Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population. Tumour Biol. 2013;34:3265-9.
3. Xia GL, Liu CB, Cao HL, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Int Hepatol Commun. 1996;5:62-73.
4. Montalto G, Iovanna JL, Soresi M, Dusetti N, Carroccio A, Barthelemy-Bialas S, et al. Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: comparison with alpha-fetoprotein. Oncology. 1998;55:421-5. (Pubitemid 28396053)
5. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25(suppl):3-8. (Pubitemid 41254588)
6. Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal and postnatal donors. Hepatology. 2007;46:2042-4.
7. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood). 2001;226:377-408. (Pubitemid 32506364)
8. Si S, Sun Y, Li Z, et al. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma. Gene Ther. 2006;13:1603-10. (Pubitemid 44688461)
9. Li MS, Li PF, Chen Q, Du GG, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol. 2004;10:819-24. (Pubitemid 38418353)
10. Zhang XL, Shi JQ, Zuo SH. A comparative study of the expression of ras oncogenic protein P21 and oncofetal protein AFP, CEA in human hepatocellular carcinoma (HCC). Zhonghua Bing Li Xue Za Zhi. 1994;23:155-8.
11. Semenkova LN, Dudich EI, Dudich IV, et al. Alpha-fetoprotein as a TNF-resistance factor for human hepato-carcinoma cell line HepG2. Tumor Biol. 1997;18:30-40. (Pubitemid 26423282)
12. Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol. 2013. doi:10.1007/s13277-013-1330-x
13. Li F, Fan YC, Gao S, Sun FK, Yang Y, Wang K. Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma. Genes Chromosom Cancer. 2014;53:90-7.
14. Yau WY, Shih HC, Tsai MH, Sheu JC, Chen CH, Chow LP. Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma. J Proteomics. 2013;94C:346-58.
15. Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D'Adamo S, Cipone M, et al. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 downregulation in hepatocellular carcinoma. Oncotarget. 2013;4:1618-31.
16. Fu Z, Ren L, Wei H, Lv J, Che X, Zhu Z, Jia J, Wang L, Lin G, Lu R, Yao Z. Effects of Tyroserleutide on phosphatidylinositol 3′-kinase/AKT pathway in human hepatocellular carcinoma cell. J Drug Target. 2014;22:146-55.
17. Colombino M, Sperlongano P, Izzo F, Tatangelo F, BottiG, Lombardi A, et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 2012;3:e259.
18. Wang RY, Chen L, Chen HY, Hu L, Li L, Sun HY, et al. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. Gastroenterology. 2013;145:1436-48.
19. Wang XJ, Feng CW, Li M. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem. 2013;380:57-66.